Needham Upgrades ACADIA Pharmaceuticals to Buy, Announces $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has upgraded ACADIA Pharmaceuticals (NASDAQ:ACAD) from Hold to Buy and set a price target of $37.

January 24, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals has been upgraded by Needham from Hold to Buy with a price target of $37.
Analyst upgrades typically lead to a positive short-term reaction in the stock price as they suggest a better outlook for the company. The new price target of $37 implies a significant upside from the current trading level, which can attract investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100